This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Eisenmenger syndrome (including Eisenmenger complex)Eisenmenger Syndrome (Including Eisenmenger Complex)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I27.8 | Special Copayment Reduction: V226 (5 years)
B. SynonymsEisenmenger complex, Eisenmenger syndrome, Eisenmenger complex, Eisenmenger reaction, Pulmonary hypertension with reversed central shunt
C. Adult onsetLikelihood of first presentation in adulthood moderate to high — the cardiac defect is congenital, but shunt reversal and cyanosis due to rising pulmonary vascular resistance commonly first appear in adolescence to adulthood
1. History1897: Victor Eisenmenger's description of a case of VSD and cyanosis → 1958: Paul Wood established the current definition (shunt reversal due to high pulmonary vascular resistance) → since the 1990s: the era of PAH-targeted therapy begins
2. CausesUncorrected intracardiac and great-vessel shunts (VSD, ASD, PDA, AV septal defect, etc.) → chronic left→right shunt → pulmonary vascular remodeling → shunt reversal (right→left)
3. GeneticsGenetic involvement according to the primary defect; frequent association of Down syndrome (trisomy 21) with AV septal defect; associated with variants in cardiac development genes such as TBX1, GATA4 and NKX2-5
4. General epidemiologyAbout 1–6% of patients with congenital heart disease (CHD); overall prevalence declining (increase in early corrective surgery). Data accumulating at Korean congenital heart disease centers
5. PathophysiologyChronic left→right shunt → pulmonary blood flow overload → endothelial injury, vascular smooth muscle proliferation and fibrosis → pulmonary vascular resistance ≥ systemic vascular resistance → shunt reversal → cyanosis and erythrocytosis
6. SymptomsExertional dyspnea, cyanosis, fatigue, syncope, hemoptysis, palpitations; symptoms of end-stage heart failure; stroke and brain abscess (paradoxical embolism)
7. SignsCentral cyanosis, clubbing, erythrocytosis; accentuated P2; right ventricular hypertrophy; ejection sound and diastolic murmur
8. ScreeningEchocardiography (shunt, estimated pulmonary artery pressure) + oxygen saturation measurement; regular follow-up for development of pulmonary hypertension in patients with a history of congenital heart disease
9. DiagnosisEchocardiography + right heart catheterization (measurement of pulmonary vascular resistance) → confirm PVR ≥ systemic vascular resistance + right→left or bidirectional shunt; anatomical assessment by cardiac CT and MRI
10. TreatmentCombination PAH-targeted therapy with macitentan, ERAs, PDE5i and prostacyclins; corrective surgery contraindicated; heart-lung transplantation is the final option; supportive therapy (iron supplementation, oxygen, contraception education)
11. PrognosisMore than 50% survive to the fifth decade (40s); survival improved after introduction of PAH-targeted therapy; main causes of death: heart failure, sudden death, pulmonary hemorrhage, stroke
12. PreventionPrimary prevention: early correction of congenital heart defects; secondary prevention: regular follow-up and early initiation of PAH-targeted therapy; avoid pregnancy, high-intensity exercise and hypoxic environments
13. ReferencesWood P (1958), Galiè N et al. JACC 2009, BREATHE-5 trial and others, 10 papers

1. History

The history of Eisenmenger syndrome begins with a case report by the Viennese internist Victor Eisenmenger (1864–1932) of Austria, who followed a 32-year-old patient for 32 years. The patient had cyanosis, dyspnea and exercise intolerance and finally died of massive hemoptysis, and autopsy confirmed a ventricular septal defect (VSD), an overriding aorta and right ventricular hypertrophy. Eisenmenger named this complex cardiac malformation "Eisenmenger complex" and published it in the German-language medical journal Zeitschrift für Klinische Medicin. At the time, however, the relationship between VSD and the pulmonary vasculature and the mechanism of shunt reversal were not sufficiently understood.

In the following decades, similar patients with cyanotic congenital heart disease were described under various names, but there was no unified pathophysiologic understanding. The decisive turning point came in 1958 with the landmark paper "The Eisenmenger syndrome, or pulmonary hypertension with reversed central shunt" published by Paul Wood (1907–1962) of Brompton Hospital in the UK. Wood recognized that the same pathophysiologic process—rising pulmonary vascular resistance due to a persistent left→right shunt and the resulting shunt reversal—occurs in various congenital heart defects including not only VSD but also ASD, PDA and other intracardiac shunts, and defined this uniformly as "Eisenmenger syndrome". He strictly defined this condition as pulmonary vascular resistance exceeding systemic vascular resistance so that a central (cardiac or great-vessel level) shunt becomes reversed (right→left) or bidirectional, and this definition is still used today.

In the 1960s–70s, advances in cardiac catheterization techniques made direct measurement of pulmonary vascular resistance (PVR) possible, and the diagnostic criteria for Eisenmenger syndrome became more precise. During this period, as advances in pediatric cardiac surgery and the introduction of cardiopulmonary bypass made early correction of congenital heart defects possible, it became clear that corrective surgery is contraindicated once pulmonary vascular disease is established. Clarification of surgical indications and contraindications became a core principle in preventing Eisenmenger syndrome.

In the 1980s–90s, as understanding of the pathophysiology of pulmonary arterial hypertension (PAH) deepened, the endothelin pathway, the nitric oxide (NO) pathway and the prostacyclin pathway emerged as key therapeutic targets. Because Eisenmenger syndrome mechanistically shares the same pulmonary vascular remodeling pathways as PAH, the concept formed that drugs developed for idiopathic PAH could also be applied to Eisenmenger syndrome. In the 2000s, BREATHE-5 (2006), the first randomized controlled trial of the dual endothelin receptor antagonist bosentan, was conducted and demonstrated that bosentan improves the 6-minute walk distance (6MWD) and significantly reduces pulmonary vascular resistance in patients with Eisenmenger syndrome. Small clinical studies of sildenafil, tadalafil, macitentan and others followed, accumulating evidence for drug treatment of Eisenmenger syndrome. Recent guidance, including a state-of-the-art review published in JACC in 2022, supports the superiority of combination PAH-targeted therapy over monotherapy.


2. Causes

Eisenmenger syndrome is not a single disease entity but a pathophysiologic end state that occurs in common across various uncorrected congenital heart defects. The core cause is chronic pulmonary vascular overload due to uncorrected intracardiac and great-vessel shunts, which causes pulmonary vascular resistance to rise irreversibly and reverses the direction of the shunt.

Types of shunt defects

Ventricular septal defect (VSD) is the most common cause of Eisenmenger syndrome, and pulmonary vascular disease progresses rapidly with large uncorrected VSDs (Qp/Qs ≥ 2). Because it is a high-flow, high-pressure shunt, pulmonary vascular remodeling is particularly rapid, and when patients survive into adulthood without correction, progression to Eisenmenger syndrome is likely. Atrial septal defect (ASD) is a low-pressure, high-flow shunt, so pulmonary vascular disease progresses more slowly than with VSD; progression to Eisenmenger syndrome often takes decades, and some patients are first diagnosed in adulthood. Patent ductus arteriosus (PDA) is a high-pressure shunt between the aorta and pulmonary artery that causes considerable pulmonary vascular disease if uncorrected. Atrioventricular septal defect (AV septal defect / AVSD) is a combined atrial and ventricular defect, particularly common in Down syndrome (trisomy 21), and is characterized by early progression to Eisenmenger physiology. Eisenmenger syndrome can also occur in other complex congenital heart malformations such as truncus arteriosus, transposition of the great arteries (TGA) and univentricular heart.

Common pathway of pulmonary vascular remodeling

Regardless of the type of causative defect, chronic pulmonary vascular overload follows the common pathway of pulmonary vascular endothelial dysfunction → vascular smooth muscle cell proliferation → medial hypertrophy → intimal fibrosis → plexiform arteriopathy → irreversible rise in pulmonary vascular resistance (PVR). When PVR exceeds or equals systemic vascular resistance (SVR), the shunt direction reverses (right→left or bidirectional), causing systemic hypoxemia and cyanosis.

Special relationship with Down syndrome

Trisomy 21 (Down syndrome) has a high frequency of various congenital heart defects including AVSD, pulmonary vascular reactivity greater than in patients with a normal karyotype, and a markedly higher risk of early progression to Eisenmenger syndrome without appropriate corrective surgery. Small studies support the long-term benefit of bosentan treatment in patients with Eisenmenger syndrome associated with Down syndrome.


3. Genetics

Because Eisenmenger syndrome itself is not a genetic disease but a complication state of congenital heart defects, genetic considerations focus on the genetic background of the causative heart defect.

Genetic causes of congenital heart defects

A genetic cause is identified in about 25–30% of congenital heart defects. Chromosomal abnormalities: in trisomy 21 (Down syndrome), heart defects including AVSD are present in about 50%, among whom the risk of progression to Eisenmenger syndrome is high. 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome) causes conotruncal malformations (TOF, IAA, VSD), with TBX1 haploinsufficiency being central. 45,X (Turner syndrome) is associated with aortic anomalies (coarctation of the aorta, bicuspid aortic valve).

Monogenic variants: germline mutations in cardiac development transcription factor genes such as GATA4 (8p23.1), NKX2-5 (5q35) and TBX5 (12q24.1) are associated with familial ASD and VSD. MYH6 (α-myosin heavy chain gene) is also associated with some ASDs. Regarding predisposition to pulmonary arterial hypertension itself, BMPR2 (bone morphogenetic protein receptor 2) gene variants are found in about 70–80% of primary PAH, and their role in Eisenmenger syndrome is under study, as they may selectively influence the rate of progression of pulmonary vascular disease.

Genetic counseling

In patients with congenital heart defects with Eisenmenger syndrome, chromosomal analysis and gene panel testing are considered. Genetic counseling is particularly important for AVSD (differentiation of Down syndrome), conotruncal malformations (22q11.2 deletion FISH/CMA) and familial ASD/VSD (gene panel including GATA4 and NKX2-5).


4. General epidemiology

The epidemiology of Eisenmenger syndrome differs greatly by country and era depending on the accessibility and timing of corrective surgery for congenital heart defects.

Incidence and prevalence

In developed countries, with the universalization of congenital heart surgery, the prevalence of Eisenmenger syndrome continues to decline. Earlier reports estimated that 4–6% of patients with congenital heart defects progressed to Eisenmenger syndrome, but this has recently fallen to about 1–3%. The absolute prevalence is estimated at about 5–10 per million population in Western European countries and may still be higher in countries with poor access to medical care. Korean studies report that about 3–5% of patients at adult congenital heart disease centers have Eisenmenger syndrome.

Sex and age distribution

Congenital heart defects themselves occur at similar frequencies in males and females, but there is a tendency toward female predominance for ASD and slight female predominance for VSD and PDA. The age of onset of Eisenmenger syndrome differs by defect type. With a large VSD or AVSD, Eisenmenger physiology may already develop in childhood or adolescence, whereas with ASD pulmonary vascular disease often first appears in adulthood (the 30s–40s or later). More adult patients with Eisenmenger syndrome are occurring in low- and middle-income countries.

Status in Korea

In Korea, outcomes of congenital heart surgery are among the best in the world, and early correction of major congenital heart defects is universal. As a result, new cases of Eisenmenger syndrome have decreased greatly, but adult patients who missed the opportunity for correction in the past and immigrant patients from abroad (countries with poor access to medical care) are becoming patients of adult congenital heart disease clinics.


5. Pathophysiology

The pathophysiology of Eisenmenger syndrome is understood as centering on pulmonary vascular remodeling due to chronic pulmonary blood flow overload and an irreversible rise in pulmonary vascular resistance (PVR). This process is a complex chain of reactions involving multiple molecular and cellular mechanisms.

Early stage: increased pulmonary blood flow and endothelial dysfunction

An uncorrected left→right shunt delivers blood flow several times normal to the pulmonary vascular bed. This chronic overload applies mechanical shear stress and stretch to pulmonary artery endothelial cells, causing endothelial dysfunction. The damaged endothelium reduces production of vasodilators (nitric oxide, prostacyclin) and increases expression of vasoconstrictor and growth factors (endothelin-1, thromboxane A2, TGF-β, etc.). This imbalance is the starting point of pulmonary vascular remodeling.

Intermediate stage: structural pulmonary vascular remodeling

As endothelial dysfunction persists, structural changes accumulate in the pulmonary artery walls. Proliferation and hypertrophy of vascular smooth muscle cells (VSMC) cause medial thickening, and subendothelial fibroblast proliferation causes intimal fibrosis and proliferation. At this stage, partial vascular reactivity is still preserved, and some response may be seen on acute vasoreactivity testing. With further progression, occlusive intimal proliferation in the pulmonary arterioles, irreversible medial fibrosis and the most severe change, plexiform lesions, form. Plexiform lesions are a characteristic finding in which pulmonary arterioles become entangled with intravascular cell clusters to form new microvessels, and at this stage the lesions are irreversible.

Late stage: rising PVR and shunt reversal

When pulmonary vascular resistance (PVR) approaches or exceeds systemic vascular resistance (SVR), the shunt direction reverses to bidirectional or right→left. Because of the right→left shunt, deoxygenated venous blood enters the systemic circulation directly and chronic hypoxemia develops. In compensation, erythropoietin (EPO) secretion increases → secondary erythrocytosis develops, and hemoglobin levels rise markedly. A high hematocrit contributes to improved oxygen-carrying capacity, but increased blood viscosity raises the risk of thrombosis and stroke.

Mechanisms of systemic complications

Chronic hypoxemia is the cause of a multisystem disease that goes beyond simple cyanosis to cause multiorgan damage. Kidneys: glomerular changes, increased uric acid, reduced renal function. Nervous system: stroke and brain abscess due to paradoxical embolism. Hematologic system: erythrocytosis, iron deficiency (due to hemodilution and misuse of repeated phlebotomy), platelet dysfunction, coagulation abnormalities. Musculoskeletal system: uric acid deposition (gout), hypertrophic osteoarthropathy.


6. Symptoms

The symptoms of Eisenmenger syndrome arise from chronic hypoxemia, right ventricular failure and erythrocytosis, starting with mild exertional symptoms early on and progressing to severe symptoms at rest in the late stage.

Respiratory symptoms

Exertional dyspnea is the most common early symptom. Although oxygen demand increases during exercise, additional oxygenation is not possible while the pulmonary→systemic shunt is reversed, so hypoxemia worsens and dyspnea results. As the disease progresses, dyspnea appears during daily activities and eventually even at rest. Hemoptysis occurs in 10–20% of patients and is due to dilation and rupture of bronchial vessels, pulmonary artery thrombosis or pulmonary infarction. Hemoptysis is mostly small in volume, but rarely massive bleeding can cause sudden death. Chest pain may occur due to compression from pulmonary artery dilation, right ventricular ischemia, pulmonary infarction and other causes.

Cardiac and vascular symptoms

Palpitations and atrial and ventricular arrhythmias are important late complications of Eisenmenger syndrome. Atrial fibrillation, atrial flutter, ventricular arrhythmias and others due to right ventricular hypertrophy and dilation are the main causes of sudden death. Syncope occurs because cardiac output cannot be increased despite the fall in systemic vascular resistance during exercise, and is regarded as a symptom of poor prognosis. In the late stage, the typical signs of fatigue at rest, leg edema, ascites and right ventricular failure appear.

Neurologic symptoms

Through paradoxical embolism via the right→left shunt, stroke (ischemic or hemorrhagic), transient ischemic attack (TIA) and brain abscess may occur. In particular, during oral and intravenous catheter procedures, air emboli or bacteria can enter the left heart directly, so prevention of bacteremia is important.


7. Signs

On physical examination, the characteristic signs of Eisenmenger syndrome reflect the consequences of central cyanosis, right ventricular overload and erythrocytosis.

Inspection and palpation findings

Central cyanosis is observed in the oral mucosa, lips, nails and elsewhere and, unlike peripheral cyanosis, does not disappear with warming. Digital clubbing is a characteristic finding of chronic hypoxemia in which the tips of the fingers and toes enlarge cylindrically. In ASD, when cyanosis and clubbing predominantly of the lower limbs (normal hands, cyanotic feet) are observed, this suggests Eisenmenger syndrome due to PDA (differential cyanosis). Elevated jugular venous pressure (elevated JVP), right ventricular heave and a palpable right ventricular impulse at the left sternal border are observed.

Auscultation findings

An accentuated P2 (loud P2) reflecting pulmonary arterial hypertension is characteristic. When shunt reversal occurs, the systolic shunt murmur disappears or diminishes (paradoxically, disappearance of the murmur signifies worsening). A Graham Steell murmur (early diastolic decrescendo murmur at the pulmonic valve area) due to pulmonic valve regurgitation may be heard. A right ventricular third heart sound (S3) and a right-sided ejection click are also observed.

Laboratory findings

Markedly elevated hemoglobin and hematocrit (Hb 16–22 g/dL or higher), increased mean corpuscular volume (MCV), or microcytosis (microcytes) due to iron deficiency. Thrombocytopenia, coagulation factor abnormalities (possible prolongation of PT/aPTT). Elevated serum uric acid, elevated creatinine (reduced renal function). On arterial blood gas, decreased PaO2 and decreased SaO2.


8. Screening

Screening for Eisenmenger syndrome is mainly done by monitoring for the development of pulmonary vascular disease in patients with identified congenital heart defects.

Echocardiography

Echocardiography is the key screening tool. Transthoracic echocardiography (TTE) is used to confirm structural defects, estimate pulmonary artery systolic pressure from the tricuspid regurgitation velocity (RVSP ≥ 40 mmHg used as the threshold for suspected PAH), assess right ventricular size and function, and confirm shunt direction (color Doppler). Bubble echocardiography (agitated saline contrast) can directly confirm the presence of a right→left shunt (the route of paradoxical embolism).

Oxygen saturation measurement

Measurement of SpO2 at rest and during exercise is a simple and useful screening tool. SpO2 < 92% at rest or a significant decrease in SpO2 during exercise strongly suggests progression of Eisenmenger syndrome or PAH. Differential cyanosis (lower-limb SpO2 < upper-limb SpO2) is a specific finding in Eisenmenger syndrome due to PDA.

Follow-up screening protocol

Adult congenital heart disease (ACHD) guidelines recommend echocardiographic follow-up at least every 1–2 years in all patients with uncorrected or partially corrected heart defects and in patients with residual shunts even after correction. An immediate evaluation pathway should be in place for worsening symptoms or decreasing SpO2.


9. Diagnosis

Confirmation of Eisenmenger syndrome requires identification of a structural heart defect and fulfillment of hemodynamic criteria by right heart catheterization.

Right heart catheterization (RHC)

RHC is the gold standard for diagnosing Eisenmenger syndrome. Measurements: mean pulmonary artery pressure (mPAP ≥ 25 mmHg), pulmonary vascular resistance (PVR ≥ 5 Wood units or 50% or more of systemic vascular resistance), pulmonary artery wedge pressure (PAWP ≤ 15 mmHg to exclude a left heart cause), Qp/Qs (shunt ratio). Eisenmenger syndrome is diagnosed when shunt reversal or a bidirectional shunt is confirmed and PVR equals or exceeds SVR. On acute vasoreactivity testing with inhaled oxygen or NO, vascular reactivity in Eisenmenger syndrome is absent or very limited, so there is almost no indication for CCBs.

Cardiac CT and MRI

Cardiac CT angiography: pulmonary artery anatomy, presence of pulmonary artery thrombosis, bronchial artery dilation (evaluation of the cause of hemoptysis). Cardiac MRI: accurate quantification of right ventricular volume and function, myocardial fibrosis (late gadolinium enhancement), anatomical assessment of the shunt. CMR can accurately assess RV function without radiation exposure and is useful for follow-up.

Other diagnostic tests

6-minute walk test (6MWT): a key indicator of exercise capacity and for tracking treatment response. BNP/NT-proBNP: reflects the degree of right ventricular failure; a prognostic indicator. Pulmonary function tests: assessment of restrictive ventilatory impairment (lung compression from pulmonary vascular dilation) and the degree of hypoxemia.


10. Treatment

Treatment of Eisenmenger syndrome consists of PAH-targeted therapy, supportive therapy and, ultimately, heart-lung transplantation. Once pulmonary vascular disease is established, corrective surgery of the heart defect is absolutely contraindicated.

PAH-targeted therapies

Endothelin receptor antagonists (ERA): the dual ERA bosentan is the first drug to demonstrate improvement in 6-minute walk distance and reduction in PVR in the BREATHE-5 randomized controlled trial (2006). The selective ERA ambrisentan is also used in Eisenmenger syndrome. Macitentan is a second-generation ERA with improved selectivity and efficacy compared with bosentan, and long-term safety and efficacy trials are under way.

PDE5 inhibitors (PDE5i): sildenafil induces pulmonary vasodilation via the NO pathway (inhibition of cGMP degradation) and shows improvement in 6MWD and functional class in Eisenmenger syndrome. Tadalafil, a once-daily agent with the same mechanism, is also used. ERA + PDE5i combination therapy tends to be superior to monotherapy and is also recommended in Korean PAH clinical practice guidelines.

Prostacyclin pathway: intravenous epoprostenol, subcutaneous treprostinil, inhaled iloprost, oral selexipag and others are used in combination or alone in severe Eisenmenger syndrome.

Supportive care

Correction of iron deficiency: iron deficiency is more common than expected in patients with erythrocytosis (microcytic erythrocytosis), and iron supplementation improves exercise capacity and quality of life. Phlebotomy is performed only in a limited way for symptomatic excessive erythrocytosis (Hct > 65%, headache or thrombotic symptoms); asymptomatic or repeated phlebotomy is contraindicated because it worsens iron deficiency and increases stroke risk. Oxygen administration: continuous oxygen administration has not demonstrated a survival benefit in hypoxemic Eisenmenger syndrome, but it is used for symptom relief. Anticoagulation: indications are unclear, and balance against the risk of bleeding (especially hemoptysis) is needed. It is considered selectively when there is pulmonary artery thrombosis or atrial fibrillation. Contraception education: pregnancy is a contraindicated situation in Eisenmenger syndrome with maternal mortality reaching 30–50%, and strong contraception education and specialized management are needed.

Heart-lung transplantation

In end-stage patients refractory to PAH-targeted therapy, heart-lung transplantation (HLTx) or lung transplantation + correction of the heart defect is the final treatment option. Five-year survival is about 50% and 10-year survival about 30%, outcomes similar to those of heart-lung transplantation in general. Maintaining the patient's condition with PAH-targeted therapy during the transplant waiting period is important.


11. Prognosis

The prognosis of Eisenmenger syndrome differs greatly depending on the time of diagnosis and treatment conditions. In the era before PAH-targeted therapy, average survival was 20–30 years after diagnosis, relatively favorable compared with primary PAH. This is because the right ventricle is congenitally adapted to high afterload, and the right→left shunt acts as a "safety valve" that partly suppresses the development of acute right heart failure.

Survival data

Large cohort studies have confirmed that more than 50% of patients with Eisenmenger syndrome survive into their 40s–50s. However, survival is markedly lower than in patients with congenital heart defects without PAH and in the general population. In cohorts after the introduction of PAH-targeted therapy (especially bosentan), improvements in 5-year survival and clinical functional indicators have been reported.

Prognostic factors

Poor prognostic factors: WHO functional class III/IV, SpO2 < 85%, history of syncope, low 6MWD (< 350m), high NT-proBNP, reduced right ventricular function (echocardiography/CMR), iron deficiency anemia, atrial fibrillation. Earlier death is generally reported with associated Down syndrome, but there are also studies showing a good response to bosentan treatment.

Main causes of death

The main causes of death are progressive right heart failure (most common), sudden cardiac death (arrhythmia), massive hemoptysis, stroke and brain abscess, and deaths related to noncardiac surgery and pregnancy.


12. Prevention

Prevention of Eisenmenger syndrome centers on early detection and timely correction of congenital heart defects, and once it has developed, it is subdivided into prevention of worsening and management of complications.

Primary prevention: early correction

Correcting VSD, ASD, PDA, AVSD and others by surgery or catheter intervention before pulmonary vascular disease becomes irreversibly established is the only sure way to prevent Eisenmenger syndrome. The timing of correction is individualized according to the size and location of the defect, Qp/Qs and pulmonary vascular reactivity. Correction within 6 months after birth is recommended for most large VSDs. Early echocardiography in neonates and infants suspected of having congenital heart defects is important.

Secondary prevention: suppressing progression

When pulmonary vascular disease has already begun, it is important to start PAH-targeted therapy (ERA, PDE5i, prostacyclin) early to suppress the progression of rising PVR. Pregnancy is the most dangerous situation in Eisenmenger syndrome, and strict contraception and preconception counseling are essential. Limiting exposure to hypoxic environments (high-altitude travel, indiscriminate air travel), preventing dehydration (reducing thrombosis risk), preventing bacterial endocarditis from systemic infection (antibiotic prophylaxis before dental extraction and invasive procedures) and low-dose iron supplementation (correction of iron deficiency) are recommended.

Tertiary prevention: management of complications

Prompt evaluation and establishment of a recurrence prevention strategy when stroke or TIA occurs. Arrhythmia monitoring and antiarrhythmic treatment. In end-stage patients, a palliative approach including heart-lung transplantation and quality-of-life–centered management. Ongoing follow-up at a specialized ACHD center contributes to improved prognosis.


13. References

  1. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J. 1958;2(5098):701–709. PMID: 13572874
  2. Galiè N, et al. Insights into the pathogenesis and treatment of Eisenmenger syndrome. Eur Heart J. 2011;32(16):1932–1934. doi:10.1093/eurheartj/ehr030
  3. Gatzoulis MA, et al. Eisenmenger syndrome: a clinical perspective in a new therapeutic era. J Am Coll Cardiol. 2009;53(9):733–740. PMID: 19245962
  4. Galiè N, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicentre, double-blind, randomised, placebo-controlled study (BREATHE-5). Lancet. 2006;368(9554):1091–1097. PMID: 17011944
  5. Broberg CS, et al. Prevalence of left atrial dilation in adults with Eisenmenger physiology. Int J Cardiol. 2011;153(2):150–156. PMID: 20554031
  6. Dimopoulos K, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010;121(1):20–25. PMID: 20026785
  7. Diller GP, et al. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation. 2015;132(22):2118–2125. PMID: 26510699
  8. Lammers AE, et al. Update on Eisenmenger syndrome — review of pathophysiology and recent progress in risk assessment and management. J Clin Med. 2024. PMC11658362
  9. Oechslin E, et al. Eisenmenger syndrome: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(12):1183–1197. doi:10.1016/j.jacc.2022.01.022
  10. Baumgartner H, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563–645. doi:10.1093/eurheartj/ehaa554